Show simple item record

dc.contributor.authorTurk, HM
dc.contributor.authorKocyigit, A
dc.contributor.authorAliyev, A
dc.contributor.authorCelik, RS
dc.contributor.authorSeker, MESUT
dc.contributor.authorCoban, E
dc.contributor.authorDemir, T
dc.contributor.authorBaydas, T
dc.date.accessioned2020-02-02T20:59:35Z
dc.date.available2020-02-02T20:59:35Z
dc.date.issued2019-07-29T00:00:00Z
dc.identifier.urihttps://openaccess.bezmialem.edu.tr/handle/20.500.12645/14046
dc.description.abstractObjective: M30 and M65 levels reflect tumor cell activity in patients with epithelial cancer. Cytokeratin 18 is one of the cell skeletal elements. M30 is a apoptotic marker of cytokeratin 18. M65 levels are both an apoptosis and a necrosis marker. The aim of our study was to determine the predictive value of M30 and M65 levels in neoadjuvant treatment of breast cancer.
dc.subjectTurk H., Aliyev A., Celik R., Seker M., Coban E., Demir T., Baydas T., Kocyigit A., -Usefulness of serum M30 and M65 levels to predict response to neoadjuvant chemotherapy in patients with breast cancer.-, Current problems in cancer, ss.100497, 2019
dc.titleUsefulness of serum M30 and M65 levels to predict response to neoadjuvant chemotherapy in patients with breast cancer.
dc.typeArticle
dc.identifier.scopus85069844749
dc.identifier.doi10.1016/j.currproblcancer.2019.06.009
dc.identifier.pubmed31371034
local.publication.isinternational1
dc.contributor.institutionauthorŞEKER, Mesut


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record